RXi Pharmaceuticals Initiates Phase 1/2 Trial For Scarring Of Wet-Age Related Macular Degeneration

RXi Pharmaceuticals announced that it has initiated its Phase 1/2 trial for retinal scarring of Wet-Age related macular degeneration -- Wet AMD.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.